Kornimate/medical-research-clean huggingface dataset:
microvascular dilatation after endogenous induced hyperinsulinemia

Conditions: Hypertension; Obesity

Summary: in this study we will examine if the insulin-induced microvascular effects will occur after a physiological stimulus (i.e. a oral glucose tolerance test). with that the physiological importance of the insulin-induced microvascular dilatation can be elucidated. in this study we hypothesize that oral glucose intake and consequently the endogenous induced hyperinsulinemia will lead to insulin-induced microvascular dilatation in healthy normotensive subjects. furthermore, we suggest that the insulin-mediated microvascular dilatation, resulting from this physiological induced hyperinsulinemia, will be less in hypertensive and obese subjects compared to healthy controls.


Eligibility criteria:
inclusion criteria: healthy normotensive subjects: 1. 18-60 years 2. caucasian 3. blood pressure \<140/90 mmhg obese normotensive subjects: 1. 18-60 years 2. caucasian 3. blood pressure \<140/90 mmhg 4. bmi 30-38kg/m2 hypertensive subjects: 1. 18-60 years 2. caucasian 3. untreated hypertension \>140/90mmhg. exclusion criteria for healthy normotensive and hypertensive subjects: 1. obesity (bmi\>27kg/m2) 2. cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure) 3. diabetes mellitus according to the criteria of the ada 4. smoking 5. alcohol use \>4u/day 6. use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, nnsaids) 7. pregnancy 8. wearing contact lenses for normotensive obese subjects: 1. cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure) 2. impaired glucose tolerance or diabetes mellitus according to the criteria of the ada 3. smoking 4. alcohol use \>4u/day 5. use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, nnsaids) 6. pregnancy 7. wearing contact lenses

Keywords: microcirculation insulin hypertension obesity
quantifying the trainability of peripheral nerve function in young and older adults.

Conditions: Nerve Degeneration; Healthy Aging

Summary: the purpose of this project is to identify the effects of hand grip resistance training on nerve speed of the hand muscles and to quantify whether age plays a role in those effects. two groups (young and older adults) underwent a 4-week resistance training intervention with nerve conduction velocity measured before and after. there were also two control groups (young and older adults) who performed the testing 4 weeks apart, but did not engage in the intervention.

studies have shown that nerve speed slows with advancing age. as a result, slower nerves may result in slower movement speed and can alter response time. the investigators propose that a resistance training intervention may elicit positive adaptations to the nerves. the purpose of this project is to identify the effects of hand grip resistance training on nerve speed of the hand muscles and to quantify whether age plays a role in those effects. two groups (young and older adults) underwent a 4-week, at-home, resistance training intervention with nerve conduction velocity (m/s) measured before and after. there were also two control groups (young and older adults) who performed the testing 4 weeks apart, but did not engage in the intervention. other outcome measures included nerve size, via ultrasound, maximal handgrip strength, and hand dexterity.

Eligibility criteria:
inclusion criteria: * apparently healthy adults 18 - 100 years old. exclusion criteria: * if you have been notified by a physician to refrain from exercise due to cardiovascular issues. * known orthopedic or neuromuscular limitations or illness of the upper extremities. * known neuromuscular disorders. * individuals that are experiencing a fever (\> 100.4° f) or have identified as symptomatic on the covid-19 screening questionnaire may not participate at this time.
magnetic resonance imaging in acute st-elevation myocardial infarction

Conditions: Acute ST-Elevation Myocardial Infarction

Summary: cardiovascular magnetic resonance imaging enables comprehensive assessment of cardiovascular function, morphology and pathology. the investigators aim to evaluate the nature and clinical significance of magnetic resonance imaging parameters in patients presenting with first acute st-elevation myocardial infarction.


Eligibility criteria:
inclusion criteria: * first st-elevation myocardial infarction according to the european society of cardiology/american college of cardiology committee criteria * primary percutaneous coronary intervention within 24 hours after symptom onset exclusion criteria: * age \< 18 years * any history of a previous myocardial infarction or coronary intervention * clinically unstable patients (killip class \>2) * renal failure (estimated glomerular filtration rate \< 30 ml/min/1.73 m2) * contraindications to cardiac magnetic resonance imaging (pacemaker, cerebral aneurysm clip, orbital foreign body, known or suggested contrast allergy to gadolinium, claustrophobia) * inability to provide informed consent
alflutinib versus alflutinib plus chemotherapy for nsclc

Conditions: NSCLC

Summary: aim: the aim of this study is to investigated whether the combination of alflutinib with cytotoxic chemotherapy might hold additive efficacy, as well as tolerability .

alflutinib is a third-generation epidermal growth factor receptor (egfr) tyrosine kinase inhibitor (tki) that is active in the central nervous system (cns) and which potently and selectively inhibits mutant forms of egfr with both tki-sensitising (activating) mutations and the t790m resistance-conferring mutation. however, resistance to alflutinib inevitably emerges. one promising strategy to further improve patient prognosis and to approach a cure is combination therapy with alflutinib and other agents such as cytotoxic chemotherapeutic drugs.

Eligibility criteria:
inclusion criteria: * histologically or cytologically diagnosed non-squamous nsclc of stage iiib or iv (based on the 7th edition of the tnm classification) or recurrent; * an egfr mutation, including an exon-19 deletion (ex19del), l858r, or other (l861q, g719a, g719c, or g719s), as well as the t790m mutation of egfr as detected in a tissue or liquid biopsy sample obtained after disease progression during first-line egfr-tki (gefitinib, erlotinib, or afatinib) treatment; * who performance status of 0 or 1; * no prior neoadjuvant or adjuvant chemotherapy in the 12 months preceding study enrollment; * adequate bone marrow reserve and organ function. exclusion criteria: * treatment with an egfr-tki within 7 days of the first dose of the study treatment; * symptomatic cns metastases; * evidence of interstitial pneumonia, pulmonary fibrosis, or radiation pneumonitis requiring steroid treatment as revealed by a computed tomography (ct) scan.

Keywords: nsclc ，egfr(t790m)，alflutinib
art therapy in obstetric patients

Conditions: Pregnancy Related; Depression

Summary: this is a prospective study examining the potential impact art therapy has on postpartum depression and mother-baby bonding in women. women who receive care at washington hospital center's will be recruited for this study.

the purpose of this research study is to assess whether alternative mental health interventions positively impacts maternal-infant bonding and postpartum depression rates in women. postpartum depression continues to be a prevalent concern for mothers and families in the united states, with current estimates demonstrating 10-20% of women being diagnosed within one year of birth. the risks of developing postpartum depression are not well known, with maternal anxiety and stress during pregnancy being one of the proposed predisposing factors. women with high-risk pregnancies are particularly susceptible to higher levels of stress and depression, during their pregnancy thus leaving them at great risk for postnatal depression. given this association, finding ways to alleviate stressors is important. music therapy is a known intervention linked with improved outcomes in women undergoing procedural interventions, including labor and delivery. art therapy is also associated with improved outcomes, though outside of obstetrics. in elderly women with depression and those with breast cancer diagnoses, visual art therapy has been shown to be superior to other non-medicinal interventions in improving mood. current data is both qualitative as well as quantitative, demonstrating positive impacts on patients. while evidence exists to support the utilization of these alternative forms of therapy, they have not been adequately applied to pregnant and postpartum women outside of music therapy. with the understanding that other art forms are tied with improvement in anxiety, depression, and quality of life, the implementation in this special patient population is paramount. investigating how a relatively benign intervention can possibly promote improvement in maternal mental health, thus allowing for better mother-baby bonding in the first year of life, is key in finding ways to support the growth and development of healthy families.

Eligibility criteria:
inclusion criteria: * participants will have to be eighteen years of age or older * in the second trimester of pregnancy at time of recruitment * speak and read english as their primary language * have access to a reliable internet/wifi connection to participate in therapy sessions * plan to deliver at washington hospital center exclusion criteria: - women who do not meet those criteria
adagrasib in combination with bi 1701963 in patients with cancer (krystal 14)

Conditions: Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Lung; Malignant Neoplastic Disease

Summary: this study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of mrtx849 (adagrasib) in combination with bi 1701963 in patients with advanced solid tumors that have a kras g12c mutation.

this study will evaluate safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics and clinical activity of mrtx849 (adagrasib) in combination with bi 1701963 in patients with advanced solid tumors with a kras g12c mutation. mrtx849 is an orally available small molecule inhibitor of kras g12c and bi 1701963 is a sos1 pan-kras inhibitor.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a solid tumor malignancy with kras g12c mutation (phase 1b must be either non-small cell lung cancer or colorectal cancer) * unresectable or metastatic disease * no available treatment with curative intent * adequate organ function exclusion criteria: * history of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * other active cancer * cardiac abnormalities

Keywords: kras g12c sos1 inhibitor nsclc crc non small cell lung cancer colon cancer advanced solid tumor metastatic cancer pancreatic cancer adagrasib
natural supplements for unipolar depression

Conditions: Unipolar Depression

Summary: this study is being conducted to determine the clinical response rate for the regimen of l-methionine, betaine and folate for unipolar depression.

the study is 6 weeks long, with 9 clinical visits. all visits will take place at our location in massachusetts.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of a mdd or ddnos; clinical indication for treatment of current depressive symptoms; hds \> 18; women of reproductive potential must use an acceptable method of birth control exclusion criteria: * treatment with another psychotropic drug; history of mania or hypomania; history of bipolar illness in first-degree relatives; active homicidality; pregnant; trying to become pregnant, or nursing; unstable medical condition; current substance abuse in the past month; history of sulfa allergy
small bowel mucosal healing induced by adalimumab in crohn's disease patients as assessed by capsule endoscopy

Conditions: Crohn's Disease

Summary: the study hypothesis is that adalimumab induces mucosal healing in the small bowel and that mucosal healing correlates with disease activity. 30 patients with isolated active small bowel crohn's disease which are candidates to receive anti-tnf treatment will be included in the study. all patients will undergo patency capsule examination and capsule endoscopy afterwards. small bowel endoscopic disease severity will be assessed by the capsule endoscopy crohn's disease activity index (cecdai). the patients will receive adalimumab (humira)injections (160mg,80mg and 40mg every 2 weeks ) for 12 weeks. on week 14 a second capsule endoscopy will be performed and cecdai calculated again. the patients clinical condition, cdai,ibdq and laboratory results including crp, cbc and fecal calprotectin will be assessed on weeks o, 7 and 14 and results will be compared with the endoscopic score.


Eligibility criteria:
inclusion criteria: 1. isolated small bowel crohn's disease. 2. age ≥18. 3. active disease (cdai≥220). exclusion criteria: 1. known fixed stricture in the small intestine. 2. former small bowel obstruction or obstructive symptoms. 3. patients expected to undergo small bowel surgery in the near future or had intestinal surgery in the previous 6 months. 4. colonic disease (except ileocecal valve area). 5. anti-tnf treatment in the last 3 months. 6. sensitivity or lack of response to previous adalimumab treatment. 7. current gastrointestinal infection. 8. history of malignant disease (except bcc of skin). 9. congestive heart failure, severe renal or hepatic dysfunction. 10. patients suffering from tuberculosis, hepatitis b or c. 11. pregnancy or unwillingness to use contraception during study period. 12. dysphagia or swallowing disorders 13. gastroparesis or severe gastrointestinal motility dysfunction. 14. patients with cardiac pacemaker or implanted cardioverter devices. 15. unable to sign informed consent.

Keywords: crohn's disease small bowel mucosal healing capsule endoscopy adalimumab small bowel crohn's disease
the efficacy of melatonin in sleep problems of hemodialysis and peritoneal dialysis patients

Conditions: Hemodialysis; Peritoneal Dialysis; Sleep Problems

Summary: sleep problems can lead to a bad quality of life and a raise of morbidity, also in dialysis patients. sleep problems can be caused by a disturbance of circadian rhythms in our body. for a good regulation of these circadian rhythms a uniform external synchronisation is necessary. this is the synchronisation of the biological clock of our body by light and other influences. in case of a disturbance of the external synchronisation, due to for example naps during the day or wake periods at night, internal rhythms can be unlinked. as a result a weakened melatonin rhythm and a problematic sleep-wake cycle can be observed. most dialysis patients have sleep problems. their sleep latency is prolonged. they often take a nap during the day and their sleep efficiency is poor. there has only been one study on the melatonin rhythm of dialysis patients. the conclusion of this study was that the melatonin rhythm of dialysis patients is weakened and disturbed, probably caused by renal insufficiency. in this study no link was made between melatonin rhythm and the nature and severity of possible sleep problems. in different studies with non-dialysis patients and a disturbed melatonin rhythm, exogenous melatonin at the right time leads to a recovery of the normal rhythm and the normal biological clock and a better quality of life. the aim is to research the endogenous melatonin rhythm and to improve sleep problems of hemodialysis patients with a placebo-controlled study with exogenous melatonin. next to this a substudy is performed, in which the effect of the change of daytime to nocturnal in hospital hemodialysis on sleep and melatonin is researched.


Eligibility criteria:
inclusion criteria: * stable peritoneal dialysis * stable hemodialysis * age 18-85 years exclusion criteria: * use of hypnotics, mao inhibitors or neuroleptics * liver disease * participation in drug investigation \< 1 months to start * former use of melatonin * severe neurological/psychiatric disease * allergic to melatonin or additives
temozolomide for treatment of brain metastases from non-small cell lung cancer (study p03247)

Conditions: Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Brain Neoplasms

Summary: the purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (wbrt) plus temozolomide (tmz) versus wbrt alone. secondary objective is to demonstrate an improvement in the time to radiological cns progression with the addition of tmz to wbrt.


Eligibility criteria:
* age greater than or equal to 18 * histologically or cytologically confirmed non-small-cell lung cancer (nsclc) * at least one brain metastasis diagnosed within 30 days of randomization * brain metastases must not have been previously treated with wbrt or radiosurgery * no more than 2 sites of extracranial metastases * may have received prior radiation therapy to the primary tumor and/or systemic metastatic sites * meets protocol requirements for specified laboratory values. * written informed consent and cooperation of patient * appropriate use of effective contraception if of childbearing potential. * karnofsky performance status kps greater than 70 * score less than 2 on all criteria of the comprehensive neurological outcome scale (cnos)
advanced hybrid closed loop system (ahcl) in older patients with type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1

Summary: the trial is a randomized controlled, parallel group design study. patients will be followed up during approximatively 12 months. patients will be randomized to either the mdi/csii group which will continue their treatment as per routine procedures and the advanced hybrid closed loop system (ahcl) group which will be connected to the minimed 780g system. . at the end of the 12 month study period, we will evaluate whether the ahcl system improved glucose indices in older individuals with type 1 diabetes mellitus (t1dm) and assess whether the achl treatment improved physical capacity, frailty \& sarcopenia indices as well as quality of life and cognitive functions.

all participants will go through a screening phase that includes an eligibility assessment, informed consent forms, cognitive function assessment ( qol questionnaire, who-5 questionnaire, moca, dsst, general heath question), sarcopenia/functional status/frailty assessment ( timed up and go , 6 min walk, 10 meter walk, berg balance scale , four square step test , grip strength, 30 second chair stand, fried scale) and lab tests. after the screening, the participants will start a two week run in phase while continuing their routine procedures with an added unblinded g4 guardian standalone sensor. sensor and data will be collected for 14 days and afterwards patients will be randomized to either the mdi/csii group which will continue their treatment as per routine procedures and the ahcl group which will be connected to the minimed 780g system. both groups will have a similar number of visits in order to minimize bias. however, the ahcl group will have 2 additional visits to allow for patients to be trained on the ahcl system. after 6 months, both groups will be connected to the standalone sensor and glucose data will be collected after 2 weeks. after 12 months of the study period, all participants will undergo primary assessments, blood tests questionnaires and will finish their part in the study.

Eligibility criteria:
inclusion criteria: 1. age over 60 years 2. t1dm 3. willing to participate in a study for the specified duration 4. willing to perform ≥ 4 finger stick blood glucose measurements daily or connected to a "basket approved" cgm 5. willing to wear the system continuously throughout the study 6. treated with mdi/csii (with exclusion of 780g or other hybrid closed systems) 7. lack of advanced complications of diabetes exclusion criteria: 1. severe concurrent illness 2. laboratory abnormalities, or medications that might affect study participation, 3. severe renal impairment 4. any illness that may interfere with study procedures

Keywords: older physical capacity frailty cognitive function
effect of violent first-person shooter (fps) video games on shooting accuracy

Conditions: Gun Shot Wound

Summary: the present research tests the effects of violent shooting games on behavior within the game (pilot study) and on behavior after the game is turned off (experiment proper). the experiment proper is an exact replication of a previous study conducted in our lab that was retracted (see citation), but with a larger sample to get more reliable results (n=287 rather than n=151).

violent shooting games are used to train soldiers and police officers. this research tests whether violent shooting can train people to shoot targets in the head, both during gameplay (pilot study) and after the game is turned off (experiment proper). participants in both studies played a violent shooting game with humanoid targets that rewarded headshots, or a nonviolent shooting game that punished shots to bull's-eye targets with faces. afterward, participants shot at a mannequin with a realistic co2 gun. we anticipate that participants who play the violent game which rewards headshots to hit the mannequin's head more often than those who play the non-violent game.

Eligibility criteria:
inclusion criteria: * 18 and older * ohio state participant pool exclusion criteria: * under age 18

Keywords: first-person shooter (fps) violent video game headshot gun operant conditioning theory
the efficacy and safety of quetiapine xr in patients with schizophrenia switched from other antipsychotics

Conditions: Schizophrenia

Summary: purpose to evaluate the efficacy and safety of once-daily quetiapine extended release (xr) in patients with schizophrenia switched from other antipsychotics which were suboptimal due to insufficient efficacy or insufficient tolerability. methods: this was a 12-week, open-label study conducted in the chinese population in taiwan. quetiapine xr was administrated at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. from day 8 until the end of the study, the dose of quetiapine xr was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.


Eligibility criteria:
inclusion criteria: * the participants who were aged from 20 to 65 years and met the diagnosis of schizophrenia according to diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) were eligible for the recruitment to the clinical trial. * they also fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the positive and negative syndrome scale (panss) positive symptom subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability. exclusion criteria: * any dsm-iv-tr axis i disorder other than schizophrenia, except comorbid obsessive-compulsive disorder, anxiety disorder, eating disorders or impulse control disorders if they had been stable and had not been primary focus of treatment over the previous 6 months * an imminent risk of suicide or a danger to self or others * pregnancy or lactation * intolerance or lack of response to quetiapine ir * use of cytochrome p450 3a4 inhibitors or inducers in the 14 days preceding enrolment * administration of a depot antipsychotic injection within one dosing interval before recruitment * unstable or inadequately treated medical illness as judged by the investigator.